search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Prevention of MTX induced psychological intolerance in children with Juvenile Idiopathic arthritis.


- candidate number2372
- NTR NumberNTR844
- ISRCTNISRCTN13524271
- Date ISRCTN created22-jan-2007
- date ISRCTN requested12-jan-2007
- Date Registered NTR14-dec-2006
- Secondary IDsN/A 
- Public TitlePrevention of MTX induced psychological intolerance in children with Juvenile Idiopathic arthritis.
- Scientific TitlePhase III effectiveness multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus standard of care.
- ACRONYMGastrointestinal side effects of MTX in patients with JIA
- hypothesisThe aim of this study is to explore the incidence of MTX related gastro-intestinal in a large cohort of JIA patients. Secondly, we want to investigate the effect of psychological behavioural therapy or switch to parenteral MTX dosing to ameliorate these side effects. In a pilot study such a behavioural therapy was successful in 11 of 20 JIA patients. These patients could therefore continue the MTX, and did not need to switch to alternative medication (often more immunosuppressive, toxic and very expensive).
- Healt Condition(s) or Problem(s) studiedJuvenile idiopathic arthritis (JIA)
- Inclusion criteria1. Diagnosis: all subtypes JIA according to ILAR classification; 2. Ages 4 to 17 years; 3. MTX oral (dosing 10-20mg/m2/week); 4. Other medication: NSAID, biologicals (etanercept, infliximab, anakinra) allowed.
- Exclusion criteria1. MTX parenteral; 2. Other diagnosis; 3. Steroid usage (more than 0.2mg/kg/day); 4. Other MTX related side effects.
- mec approval receivedno
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlNot applicable
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-mrt-2007
- planned closingdate1-mrt-2010
- Target number of participants130
- InterventionsPatients will be randomised for 1. Behavioral therapy plus continuation of oral MTX (intervention); 2. Switch to parenteral MTX (control) 3. Continuation of standard of care plus anti-emetic drugs (control).
- Primary outcome1. The number of patients continuing MTX; 2. Number of patients reporting gastrointestinal side effects; 3. JIA disease activity parameters. Measured: 0, 3, 6 and 12 months.
- Secondary outcome1. JIA disease activity parameters (PRINTO core set criteria);. 2. Metabolomics and folate/homocysteine/adenosine metabolites; 3. Inflammation parameters (ESR, CRP, cytokine profiles, Tregs, MMR antibodies); 4. MTX related cytopenias. Measured: 0, 3, 6 and 12 months.
- Timepoints
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. MD., PhD. N. Wulffraat
- CONTACT for SCIENTIFIC QUERIESDr. MD., PhD. N. Wulffraat
- Sponsor/Initiator University Medical Center Utrecht (UMCU), Department of Pediatrics
- Funding
(Source(s) of Monetary or Material Support)
Medac, Pharmachmie
- Publicationspilot study submitted to Clin Exp Rheumatology
- Brief summaryMTX is currently the most widely used, effective, safe and cheapest second line anti-rheumatic drug for the treatment of Juvenile Idiopathic Arthritis (JIA) and Rheumatoid Arthritis (RA). These advantages have made MTX very successful with regard to efficacy and safety for the individual patient as well as for the health care budget. The downside of MTX is that especially after prolonged use, quite a number of JIA patients turn intolerant for the drug. This intolerance is characterized by severe gastrointestinal complaints that sometimes occur even before taking the drug. The aim of this study is to explore the incidence of MTX related gastro-intestinal in a large cohort of JIA patients. Secondly, we want to investigate the effect of psychological behavioural therapy or switch to parenteral MTX dosing to ameliorate these side effects. In a pilot study such a behavioural therapy was successful in 11 of 20 JIA patients. These patients could therefore continue the MTX, and did not need to switch to alternative medication (often more immunosuppressive, toxic and very expensive). Behavioural therapy is easy to apply and safe. In the first month it is time consuming. There are no risks for applying this in children. The benefit is that we expect that behavioural therapy will ameliorate the intolerance and prevent switch to parenteral MTX (painfull injections) or alternative (more immunosuppressive and more expensive) medication.
- Main changes (audit trail)
- RECORD14-dec-2006 - 23-jan-2007


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl